Therefore, when using TAC to treat MN, detecting the CYP3A5 * 3 gene polymorphism in patients can assist clinicians in determining the optimal initial dosage so as to achieve effective blood drug concentration in a shorter time and, thus, optimize the management of membranous nephropathy. The gene discussed is CYP3A5; the disease is membranous glomerulonephritis.